📊 DMAC Key Takeaways
Is DiaMedica Therapeutics Inc. (DMAC) a Good Investment?
DiaMedica Therapeutics is a pre-commercial biotech company with unsustainable unit economics, burning 9.1M annually against only 500K in revenue. With 4.9M cash on hand providing less than 6.5 months of operational runway, the company faces imminent capital requirements or insolvency with no visible path to profitability.
DiaMedica Therapeutics shows very weak fundamentals, with only $500K of revenue against a $24.03M net loss and deeply negative operating cash flow of $21.30M. While the balance sheet appears lightly levered and current liquidity ratios are high, the absolute cash balance of $3.33M looks thin relative to its cash burn, making funding risk the central issue. Until revenue quality improves materially or cash resources are replenished, the business profile remains highly speculative.
DiaMedica Therapeutics Inc. Key Strengths (DMAC)
- Zero debt provides financial flexibility and eliminates refinancing risk
- Strong current ratio of 9.11x ensures adequate short-term liquidity coverage
- Stockholders equity of 47.2M provides asset backing relative to liabilities
- No meaningful leverage, with debt-to-equity at 0.00x
- Strong reported near-term liquidity ratios, with current and quick ratios at 10.67x
- Equity base remains solid at $51.62M, supporting balance-sheet flexibility
DMAC Stock Risks: DiaMedica Therapeutics Inc. Investment Risks
- Critical cash depletion risk with 6.5-month runway at -9.1M annual operating cash burn rate
- Net losses deteriorating 34% year-over-year with minimal revenue generation and no demonstrated commercialization capability
- Zero insider activity over 90 days combined with unsustainable burn dynamics indicates existential viability concerns
- Extremely weak profitability, with operating margin of -5036.8% and net margin of -4805.2%
- Very low revenue base relative to expenses suggests limited commercial traction or pre-scale operations
- Cash burn is severe versus cash on hand, raising near-term financing and dilution risk
Key Metrics to Watch
- Monthly operating cash burn rate and absolute cash position
- Revenue inflection and clinical trial progress toward commercialization
- Capital raise announcements and equity dilution impact on existing shareholders
- Quarterly operating cash burn versus cash and equivalents
- Revenue growth and progress toward narrowing operating losses
DiaMedica Therapeutics Inc. (DMAC) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 9.11x current ratio provides a solid financial cushion.
DMAC Profit Margin, ROE & Profitability Analysis
DMAC vs Healthcare Sector: How DiaMedica Therapeutics Inc. Compares
How DiaMedica Therapeutics Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is DiaMedica Therapeutics Inc. Stock Overvalued? DMAC Valuation Analysis 2026
Based on fundamental analysis, DiaMedica Therapeutics Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
DiaMedica Therapeutics Inc. Balance Sheet: DMAC Debt, Cash & Liquidity
DMAC Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: DiaMedica Therapeutics Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.60 indicates the company is currently unprofitable.
DMAC Revenue Growth, EPS Growth & YoY Performance
DMAC Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2019 | $500.0K | -$1.4M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
DiaMedica Therapeutics Inc. Dividends, Buybacks & Capital Allocation
DMAC SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for DiaMedica Therapeutics Inc. (CIK: 0001401040)
📋 Recent SEC Filings
| Date | Form | Document | Action |
|---|---|---|---|
| Jun 3, 2026 | 4 | xslF345X06/form4-06032026_090625.xml | View → |
| Jun 3, 2026 | 4 | xslF345X06/form4-06032026_090653.xml | View → |
| Jun 3, 2026 | 4 | xslF345X06/form4-06032026_090622.xml | View → |
| Jun 3, 2026 | 4 | xslF345X06/form4-06032026_090650.xml | View → |
| Jun 3, 2026 | 4 | xslF345X06/form4-06032026_090620.xml | View → |
❓ Frequently Asked Questions about DMAC
What is the AI rating for DMAC?
DiaMedica Therapeutics Inc. (DMAC) has a Combined AI Grade of D from Claude (D) and ChatGPT (D) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are DMAC's key strengths?
Claude: Zero debt provides financial flexibility and eliminates refinancing risk. Strong current ratio of 9.11x ensures adequate short-term liquidity coverage. ChatGPT: No meaningful leverage, with debt-to-equity at 0.00x. Strong reported near-term liquidity ratios, with current and quick ratios at 10.67x.
What are the risks of investing in DMAC?
Claude: Critical cash depletion risk with 6.5-month runway at -9.1M annual operating cash burn rate. Net losses deteriorating 34% year-over-year with minimal revenue generation and no demonstrated commercialization capability. ChatGPT: Extremely weak profitability, with operating margin of -5036.8% and net margin of -4805.2%. Very low revenue base relative to expenses suggests limited commercial traction or pre-scale operations.
What is DMAC's revenue and growth?
DiaMedica Therapeutics Inc. reported revenue of $500.0K.
Does DMAC pay dividends?
DiaMedica Therapeutics Inc. does not currently pay dividends.
Where can I find DMAC SEC filings?
Official SEC filings for DiaMedica Therapeutics Inc. (CIK: 0001401040) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is DMAC's EPS?
DiaMedica Therapeutics Inc. has a diluted EPS of $0.00.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined grade reflects both perspectives for balanced insights.
What is DMAC's fundamental grade?
Based on our AI fundamental analysis in June 2026, DiaMedica Therapeutics Inc. has a D grade with 86% confidence. Review the strengths and risks sections above for full context. This is not investment advice.
Is DMAC stock overvalued or undervalued?
Valuation metrics for DMAC: ROE of -21.3% (sector avg: 15%), net margin of -2,008.4% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
What is DMAC's AI grade for 2026?
Our dual AI analysis gives DiaMedica Therapeutics Inc. a combined D grade for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is DMAC's free cash flow?
DiaMedica Therapeutics Inc.'s operating cash flow is $-9.1M, with capital expenditures of $8.0K. FCF margin is -1,818.0%.
How does DMAC compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -2,008.4% (avg: 12%), ROE -21.3% (avg: 15%), current ratio 9.11 (avg: 2).